Test May Predict Recurrence and Response to Immunotherapy in Melanoma Patients

Source: Genetic Engineering& Biotenology News, September 2022

Scientists at the Perlmutter Cancer Center in the NYU Grossman School of Medicine have developed an experimental test based on a composite panel of autoantibody signatures that generates a score that can be used to predict the occurrence of severe side effects or the recurrence of cancer in melanoma patients who have received immune checkpoint blockade immunotherapies—a therapeutic modality that bolsters the patients own immune system to attack malignant cells.

“The composite panel of autoantibody signatures can allow for the simultaneous risk stratification of patients according to their likelihood of recurring and suffering severe toxicity,” the authors noted.

The development of the test was in the journal Clinical Cancer Research (“Baseline serum autoantibody signatures predict recurrence and toxicity in melanoma patients receiving adjuvant immune checkpoint blockade”).
READ THE ORIGINAL FULL ARTICLE